Nuclear receptor coactivator 3

Source: Wikipedia, the free encyclopedia.
NCOA3
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_181659
NM_001174087
NM_001174088
NM_006534

NM_008679
NM_001374779

RefSeq (protein)

NP_001167558
NP_001167559
NP_006525
NP_858045

n/a

Location (UCSC)Chr 20: 47.5 – 47.66 MbChr 2: 165.99 – 166.07 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

The nuclear receptor coactivator 3 also known as NCOA3 is a protein that, in humans, is encoded by the NCOA3 gene.[5][6] NCOA3 is also frequently called 'amplified in breast 1' (AIB1), steroid receptor coactivator-3 (SRC-3), or thyroid hormone receptor activator molecule 1 (TRAM-1).

Function

NCOA3 is a transcriptional coactivator protein that contains several nuclear receptor interacting domains and an intrinsic histone acetyltransferase activity. NCOA3 is recruited to DNA promotion sites by ligand-activated nuclear receptors. NCOA3, in turn, acylates histones, which makes downstream DNA more accessible to transcription. Hence, NCOA3 assists nuclear receptors in the upregulation of gene expression.[7][8]

Clinical significance

The ratio of

breast cancer treatment.[9][10]

Several molecular mechanisms implicate NCOA3 (AIB1) in the

PIK3CA (PI3K), activating mutations in the proto-oncogene tyrosine-protein kinase Src, etc.) that lead to persistent activation of ERK and/or PIK3CA/AKT kinase pathways result, in one hand in an enhanced AIB1 transcriptional coactivation capacity,[11] and in the other hand in the inhibition of the proteasome-dependent AIB1 turn-over and therefore, in AIB1 overexpression.[12] In both conditions, the equilibrium of estrogen receptor (ER) complex formation is displaced towards a transcriptionally active complex and thus, counteracting the inhibition caused by anti-estrogenic drugs such as tamoxifen or fulvestrant (selective estrogen receptor modulators
). The result is the restoration of estrogen-sensitive gene transcription and the promotion of cancer progression and/or relapse.

Notably, tumors diagnosed with concomitant overexpression of AIB1 and

HER2/neu have worse outcome with tamoxifen therapy than all other patients combined.[13] In addition, dormant tumor cells of luminal breast cancers treated with endocrine therapy may acquire with time, mutations that alter kinase signalling pathways and ultimately enhance AIB1 oncogenic functions. Also, estrogen receptor-PAX2 complexes repress HER2/neu expression, but loss of PAX2 expression may result in de novo HER2/neu expression and initiate endocrine therapy resistance and relapse.[14]

Mechanisms for AIB1-dependent anti-estrogen therapy resistance

Interactions

Nuclear receptor coactivator 3 has been shown to

interact
with:

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000124151Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000027678Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. PMID 9252329
    .
  6. .
  7. .
  8. .
  9. ^ "Study sheds new light on tamoxifen resistance". Cordis News. Cordis. 2008-11-13. Archived from the original on 2009-02-20. Retrieved 2008-11-14.
  10. PMID 19005469
    .
  11. .
  12. .
  13. .
  14. .
  15. .
  16. .
  17. .
  18. ^ .
  19. .
  20. ^ .
  21. ^ .
  22. .
  23. .
  24. .
  25. .
  26. .
  27. .
  28. .

External links

Further reading